Table 2_Clinical effects of Yiqi-Yangyin-Huoxue granules in the management of type 2 diabe

A 12-week randomized, double-blind, placebo-controlled trial protocol for evaluating the Yiqi-Yangyin-Huoxue (YQYYHX) herbal formulation. The study, authored by Jinyi Fu, enrolled 120 participants with type 2 diabetes and early vascular aging, with recruitment running from March 2025 to December 2026. The protocol describes primary and secondary clinical outcomes, safety evaluations, and plans for metabolomic, proteomic, and metagenomic sequencing of collected samples.

Use Cases

• Analyzing clinical trial design and outcome measures for herbal interventions in diabetes based on the described primary and secondary endpoints.
• Studying the integration of multi-omics data (metabolomics, proteomics, metagenomics) in clinical research based on the planned serum and fecal sample analysis.
• Benchmarking data management practices in clinical trials based on the described use of electronic case report forms and data capture systems.

Strengths

• The protocol is for a rigorously designed trial with a randomized, double-blind, placebo-controlled structure.
• Specific sample sizes and timelines are provided, including 120 planned participants and recruitment from March 2025 to December 2026.
• The trial is registered with an international registry (ITMCTR2024000388), enhancing transparency.

Limitations

• The dataset is a 21.4 KB DOCX protocol document, not the resulting clinical trial data, which limits its use for direct analysis.
• Column-level documentation for any potential accompanying data is absent; field semantics must be inferred after download.
• Description metadata is limited; actual data quality and availability require manual inspection after download.

Provenance

Source

figshare, authored by Jinyi Fu.

Collection Method

Described as a single-center clinical trial protocol.

Time Range

Trial recruitment from March 27, 2025 to December 31, 2026.

Freshness

Last updated 2026-06-03 12:08:48; freshness should be verified.